127 filings
Page 2 of 7
8-K
5b6p5
10 May 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
kmj3ea
28 Apr 17
Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
12:00am
8-K
0mi1n0y
27 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
2cskqre
31 Mar 17
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
12:00am
8-K
mysep
16 Mar 17
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
12:00am
8-K
y90vhyj67o16p8w2qj4
27 Feb 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
f15e62
16 Feb 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
qtsuo5 r8
6 Jan 17
Regulation FD Disclosure
12:00am
8-K
sipz1xorwxveq fnkt
27 Dec 16
Other Events
12:00am
8-K
l61d2fnhy 8tkqe7
6 Dec 16
Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy
12:00am
8-K
073lc1
1 Dec 16
Regulation FD Disclosure
12:00am
8-K
dx4qrrfwdq
10 Nov 16
Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study
12:00am
8-K
ek4e tcsdrju2eahn3kz
4 Nov 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
12:00am
8-K
i4pvicjw73fywfm2
15 Sep 16
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
2panv7h6
12 Sep 16
Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million
12:00am
8-K
wa1b9 r1ga
16 Aug 16
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
12:00am
8-K
1ol2r3r
9 Aug 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
12:00am
8-K
fc51 hcpzlrrh
29 Jun 16
Regulation FD Disclosure
12:00am
8-K
c6eyl70a
29 Apr 16
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
12:00am
8-K
m1ahx xh32ys6rw
22 Apr 16
Entry into a Material Definitive Agreement
12:00am